Komori
Share Issuance and Disposal4893Noile-Immune Biotech Inc.Pharmaceuticals

Notice Concerning the Large-Scale Exercise of Stock Acquisition Rights with a Provision for Adjustment of the Exercise Price

Between 6 and 21 October 2026, 12,500 Series 14 Stock Acquisition Rights were exercised and 1,250,000 new shares were delivered. As a result, the number of unexercised stock acquisition rights decreased from 100,000 to 87,500.

Worth reading
25Immaterial
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1250000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

1,250,000 new shares (number of shares delivered between 6 and 21 October 2026)

Terms of the stock acquisition rights
Exercise price
The exercise price ranged from ¥85 to ¥136 per day. Details of the adjustment clauses and the floor price have not been disclosed.
Number of Stock Acquisition Rights
Total issued: 100,000; exercised between 6 and 21 October 2026: 12,500; currently unexercised: 87,500
Most recent equity financing
5 October 2026: Issuance of stock acquisition rights with exercise-price adjustment clauses (as described in this document)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of1,250,000 new shares (number of shares delivered between 6 and 21 October 2026)
Total number of issued shares43,399,118 shares (as of the end of the month preceding the relevant month) → Not disclosed
Exercise priceThe exercise price ranged from ¥85 to ¥136 per day. Details of the adjustment clauses and the floor price have not been disclosed.
Number of Stock Acquisition RightsTotal issued: 100,000; exercised between 6 and 21 October 2026: 12,500; currently unexercised: 87,500
Most recent equity financing5 October 2026: Issuance of stock acquisition rights with exercise-price adjustment clauses (as described in this document)
Items this document does not state (22)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This was because a large number of the stock acquisition rights with exercise-price adjustment clauses issued on 5 October 2026 were exercised during the relevant period.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning the Large-Scale Exercise of Stock Acquisition Rights with a Provision for Adjustment of the Exercise Price | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori